# Pegfilgrastim Versus Filgrastim After High-dose Chemotherapy

> **NCT00410696** · PHASE2 · COMPLETED · sponsor: **Armando Santoro, MD** · enrollment: 80 (actual)

## Conditions studied

- Hematological Neoplasms
- Tumors

## Interventions

- **DRUG:** Filgrastim
- **DRUG:** Pegfilgrastim

## Key facts

- **NCT ID:** NCT00410696
- **Lead sponsor:** Armando Santoro, MD
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2006-09
- **Primary completion:** 2008-11
- **Final completion:** 2008-11
- **Target enrollment:** 80 (ACTUAL)
- **Last updated:** 2013-07-01


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00410696

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00410696, "Pegfilgrastim Versus Filgrastim After High-dose Chemotherapy". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT00410696. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*